Freedom to Operate (FTO) for a medicinal product is the legal status of a pharmaceutical product confirming that the manufacture, import, registration, or sale of the product does not infringe valid third-party patents within a specific jurisdiction. Verification is carried out by comparing the drug’s components, active pharmaceutical ingredient (API), crystalline form, combination, manufacturing technology, and therapeutic application scheme with each independent feature of the claims of registered patents and published applications, taking the doctrine of equivalents into account.
- Object of Verification: Assessment applies not only to the active pharmaceutical substance (API) but also to polymorphic modifications, salts, excipients, dosage forms, compositions, and therapeutic dosages.
- Litigation Compliance: Launching a generic drug without verified FTO threatens interim relief measures in the form of suspended registration at the State Expert Center of the Ministry of Health (SEC MoH), customs cargo blocking, and multi-million-dollar damage claims.
- Bolar Exception: Current legislation allows the use of a patented invention exclusively for research purposes aimed at preparing the registration dossier, but strictly prohibits commercial manufacturing and inventory buildup before patent expiration.
- Combating Secondary Patents: “Evergreen” patents are subject to preliminary audit for compliance with novelty and inventive step criteria with the possibility of preemptive challenge in the Appeals Chamber or court.
The pharmaceutical market operates under conditions of extreme patent density. An error in determining the boundaries of patent rights at the R&D or import stage converts into catastrophic losses for a pharmaceutical company: customs shipment seizures, cancellation of state registration, shutdown of factory lines, and claims for originator’s lost profits. Practice shows that the formal presence of one’s own technology patent or registration certificate does not grant immunity from third-party claims. Safely launching a generic or biosimilar to the market requires a comprehensive preventive patent clearance that allows either finding a safe corridor for action or proactively dismantling competitors’ artificial patent barriers.
Pharmaceutical Business Patent Risks: Current Judicial Practice
Before moving on to the technical details of the FTO procedure, it is crucial to soberly assess the regulatory framework and practical consequences of neglecting third-party intellectual property rights. The pharmaceutical sector remains one of the most high-conflict areas: innovative pharmaceutical giants deploy complex multi-stage legal protection systems (“patent thickets”) aimed at artificially extending market exclusivity after the base patent on the active molecule expires.
Commercial threats for a company launching a generic drug without an appropriate FTO opinion are divided into procedural (operational) and material. The most dangerous tool used by originators is interim injunctions under procedural law rules. Courts increasingly seize imported batches of medicines, prohibit the State Service on Medicines and Drugs Control from issuing quality certificates, and prevent the State Expert Center of the Ministry of Health (SEC) from completing the generic registration dossier review.
| Patent Risk Category | Essence of Negative Scenario | Probability | Preventive Protection Measure |
|---|---|---|---|
| Injunction on Circulation | Court ruling prohibiting import, distribution, and sale until the dispute is resolved on the merits. | High | FTO expertise, counter-security submission, proving disproportionality of measures. |
| Blocking at SEC MoH | Suspension of state medicinal product registration or revocation of existing marketing authorization (patent linkage). | Medium / High | Using the Bolar exception, excluding references to protected indications in the dossier. |
| Customs Border Stoppage | Suspension of customs clearance based on IP Customs Register data for up to 20 working days. | Critical | Preemptive analysis of UKTZED custom codes, preliminary dialogue with customs providing FTO Legal Opinion. |
| Recovery of Compensation & Damages | Financial sanctions in the amount of the right holder’s lost profits or disgorgement of all gross commercial revenue. | Medium | Legal opinion on the absence of intent and substantial formula differences, designing around the invention formula. |
Realizing even one of these risks can completely disrupt the product launch commercial strategy, freezing the distributor’s working capital. Therefore, understanding litigation risks dictates the need for systematic preventive audits before importing or industrially manufacturing a drug.
Analysis of Active Patents: Uncovering Hidden Monopolies
A classic mistake made by many importers is checking exclusively the main patent for the basic active substance (API, active pharmaceutical substance). When the primary patent expires (standard 20 years plus a Supplementary Protection Certificate — SPC), the market is formally considered open. However, in 90% of cases, the originator creates an entire series of secondary patents:
- patents for individual salts, esters, solvates, or specific polymorphic (crystalline or amorphous) modifications of the molecule;
- patents for stable pharmaceutical compositions, mixtures, and fixed dosage combinations;
- patents for methods of treating specific nosologies (second and subsequent medical uses);
- patents for prodrug forms, administration regimens, or molecular synthesis technological schemes.
To identify these hidden monopolies, searches must be conducted comprehensively using international classifications IPC (primarily classes A61K, A61P, C07D, C07C), registration databases of the Ukrainian National Office of Intellectual Property and Innovations (UKRNOIVI / IP Office), as well as global patent arrays Espacenet and Patentscope. The main task is to identify the complete structure of the patent family by the CAS number of the active substance and uncover all active patents in the jurisdiction whose term has not yet expired.
Supreme Court Judicial Practice: Pharmaceutical Disputes
Law enforcement practice regarding the protection of pharmaceutical patents in recent years has undergone significant evolution. Courts have moved away from the formal protection of any registered monopoly right and have begun to closely examine the nature of the invention and the good faith of the parties.
The key standard of proof in such disputes remains the “rule of the full complement of features”: an invention is recognized as used if the respondent’s product sample uses every feature recited in an independent claim of the patent formula, or an equivalent feature at the date of first use. The Supreme Court has repeatedly emphasized that if at least one essential feature of the patent formula is absent in the generic composition or manufacturing technology, patent infringement does not occur.
Regarding the doctrine of equivalents, intellectual property forensic examination evaluates the so-called “triple identity test”: whether the substituted feature performs substantially the same function, in substantially the same way, to achieve the same result. If a generic company used another auxiliary polymer or another solvent that provides a therapeutic effect but alters the drug’s stability, bioavailability, or dissolution mechanism, equivalence infringement is excluded. For a comprehensive assessment of such conflicts and the protection of interests in court proceedings, specialized legal assistance in patent disputes and invention registration is applied, allowing the formation of an unassailable evidentiary base even before court proceedings commence.
Freedom to Operate Expertise: Import Protection
Recognizing legal risks, an importer faces the necessity of conducting a practical Freedom to Operate (FTO) verification. The FTO study is designed to answer a clear business question: can a specific pharmaceutical product be imported, registered, and placed into civil circulation without the risk of facing a lawsuit for third-party IP infringement?
When conducting an FTO, the fundamental territorial principle of patent law applies: patents registered in the EU, USA, or India have no legal force unless they have received national registration or have been extended to the jurisdiction via international procedures (PCT treaty). Therefore, establishing product “cleanness” in the German market does not guarantee automatic cleanness elsewhere. The temporal search depth must cover a 20-year period preceding the audit date, adjusted for the period of potential supplementary protection in accordance with local legislation governing patent term extensions for medicines.
Key Action: Complete identification of the composition and parameters of the medicinal product (API structural formula, crystal lattice, salt, quantitative composition of excipients, manufacturing technological process, summary of product characteristics).
Goal / Requirement: Formation of a detailed technical product profile based on the registration dossier or DMF (Drug Master File).
Result: Approved matrix of technical and chemical product features for comparative searching.
Key Action: Conducting searches by International Nonproprietary Names (INN), chemical descriptors (CAS, IUPAC), keywords, IPC codes, and patent owners in UKRNOIVI, Espacenet, and WIPO registers.
Goal / Requirement: Coverage of patents for inventions and utility models over the past 20–25 years, including active, extended, and published applications at the examination stage.
Result: Formation of a register of relevant title documents potentially overlapping with the product.
Key Action: Construction of a comparative table between the features of independent claims of found patents and the characteristics of the studied drug using the full complement of features rule.
Goal / Requirement: Identification of absolute matches, missing elements, and checks for equivalent substitutions in the chemical formula or composition.
Result: Patent risk map with identification of blocking patents and safe production/import zones.
Key Action: Preparation of the final official Legal Opinion and compilation of a patent form in accordance with national and international standards.
Goal / Requirement: Providing legal assessment of the importer’s or distributor’s actions, formulating strategies for patent circumvention or preparing invalidation lawsuits.
Result: Legally binding document for investment protection, customs interactions, banks, and regulatory authorities.
Even a flawless FTO report does not exist in a vacuum: it requires precise alignment with the timelines of the generic company’s regulatory actions and synchronization with regulatory authority processes.
Freedom to Operate Procedure: Search Methodology
The methodology of FTO analysis is based on a strict analytical distinction between two concepts: “patentability” and “patent freedom”. The patentability of one’s own development assesses novelty and inventive step compared to the entire known state of the art worldwide. Patent freedom assesses something entirely different: whether the drug violates clearly defined third-party rights fixed in monopoly patent formulas effective in a specific jurisdiction.
When comparing an invention formula of a pharmaceutical product, a patent attorney works using the independent claim decomposition formula:
- The preamble (features known from the state of the art) and the characterizing portion (features constituting the essence of the invention) are separated.
- Each feature is compared with the qualitative and quantitative parameters of the studied medicine sample.
- Dependent claims are analyzed; while they do not expand the scope of legal protection of the independent claim, they detail specific embodiments of the molecule or dosage form.
If at least one essential feature of the independent claim is not reflected in the drug (for example, the patent specifies a maleate salt, while the generic is created on the basis of hydrochloride, or a fundamentally different stabilizer is used that falls outside the patent ranges), the absence of patent infringement under the literal reading of the claims is recorded.
Prevention of Customs Seizures: Ensuring Safe Imports
Customs control poses a particular danger to distributors. If an intellectual property object is entered by the right holder into the relevant customs register, customs is obliged to suspend cargo clearance for 10 working days (with a possible 10-day extension) upon suspicion of infringement.
To prevent losses from transport downtime and temperature storage violations of pharmaceutical products, an importer must act proactively. When declaring goods under HS (UKTZED) codes, providing a pre-prepared Legal Opinion on patent freedom allows customs authorities to establish the absence of obvious counterfeit signs. If the right holder initiates a suspension anyway, the presence of the FTO report serves as the basis for immediately submitting reasoned objections, requesting sampling and testing, and calculating the amount of potential damages that the importer can recover from the patent holder in case of unjustified blocking of customs clearance.
Generics and the Bolar Exception: Limits of Testing
Striving to be first to market at the moment of the originator’s patent expiration (a day-one launch), generic companies must operate under the Bolar exception concept. Historically, this rule arose in U.S. case law (Roche Products v. Bolar Pharmaceutical, 1984), where the court ruled that conducting trials before patent expiration infringed inventor rights. This prompted the U.S. Congress to adopt a legislative exemption, which was later implemented into EU and local legislation.
This norm is enshrined in national laws, directly establishing that the importation of a patented medicinal product and the use of an invention exclusively for conducting research, trials, and preparing information required to obtain state registration of a medicinal product before patent expiration is not recognized as a patent infringement.
“The main legal trap of the Bolar exception lies in the erroneous interpretation of the boundaries of what is permitted. Some manufacturers believe that since they are allowed to prepare a registration dossier, they have the right to set up a production line and manufacture 100,000 packages of a drug three months before patent expiration to fill pharmacy warehouse inventories. The position of the courts here is categorical: manufacturing or importing commercial batches intended for immediate sale after ‘Day X’ is a direct patent infringement. The Bolar exception legitimizes exclusively the series necessary for validating analytical methods, bioequivalence tests, and providing samples to the regulator. Any excess beyond the scientifically justified need is regarded by courts as placing goods into commercial circulation.”
If the originator’s patent artificially extends the monopoly through minor modifications, there arises a need not just to wait out expiration dates, but to apply an active offensive strategy of judicial cancellation of bad-faith patents.
Legal Status of a Generic: Application of the Bolar Exception
A generic drug may legally remain in the development stage throughout the entire validity period of the originator’s base patent. Legal actions by a generic company under the law include:
- importing samples of substances (API) or finished forms to conduct internal laboratory research;
- conducting comparative in vitro dissolution studies and in vivo bioequivalence clinical trials;
- manufacturing pilot batches of the drug in volumes strictly regulated by Good Manufacturing Practice (GMP) requirements to confirm stability and process validation;
- submitting the registration dossier package (Common Technical Document — CTD) to the State Expert Center of the Ministry of Health.
The criterion of legitimacy in a court dispute is the purpose of the actions: if the enterprise documentation records that samples or batches were transferred to clinical sites or destroyed after testing, the corpus delicti is absent.
Preparation of the Registration Dossier: Risks of Premature Launch
The issue of interaction between patent protection and regulatory drug registration is known in global practice as “patent linkage.” State registration procedures require the applicant to submit a patent declaration stating that placing the drug into circulation does not infringe existing third-party intellectual property rights.
Originators monitor MoH orders and SEC Scientific Expert Council meetings around the clock. Upon discovering an intention to register a generic, the patent holder files a lawsuit to prohibit actions aimed at infringement, attempting to block the issuance of the registration order. To avoid this threat, generic companies time submissions so that dossier filing occurs approximately 12–18 months before the base patent expires, and the marketing authorization itself comes into effect on the day after patent monopoly expiration.
Overcoming Evergreen Patents: Judicial Challenge Strategy
When FTO analysis results indicate the presence of an artificial secondary patent blocking product launch years in advance, the only economically justified business decision is to invalidate it. In international pharma, this is known as overcoming “evergreen” patents.
The legal basis for challenging a patent is established by law: a patent can be invalidated in judicial proceedings if the patented invention fails to comply with patentability conditions, specifically novelty and inventive step. The trial requires the involvement of forensic experts, patent attorneys, and pharmaceutical specialists who must prove to the court that the “improvement” proposed by the patent holder was obvious to a person skilled in the art at the priority date of the application.
Successfully overcoming a patent barrier eliminates claim risks, but for the product’s commercial triumph, this is not enough: it is necessary to simultaneously ensure the legal protection of the new medicinal product’s commercial brand in the digital and customs environments.
Signs of Evergreen Patents: Criteria for Lack of Novelty
To timely recognize a weak secondary patent, pharmaceutical businesses must pay attention to characteristic indicators. Inventive step is absent in the following cases:
- Selection inventions without an unexpected effect: selecting a separate compound from a previously disclosed broad class of molecules (Markush formulas) if this compound lacks fundamentally new therapeutic properties.
- Simple change of dosage form: converting an injection solution into capsules or tablets without changing the pharmacokinetic profile.
- New dosage regimens or therapeutic schemes: for example, moving from twice-daily administration to once-daily dosing with modified release, if the sustained-release technology itself is already known from the state of the art.
- Combinations of known substances: mixing two active components where the effect equals the simple arithmetic sum of each action (lacking pharmacological synergism).
Identifying such signs provides a high probability of successfully canceling the monopoly through an opposition procedure at the Appeals Chamber or a direct lawsuit in the commercial court.
Invalidating a Patent: Proof Algorithm for Obviousness
A tactical lawsuit against a patent holder requires meticulous work with evidence. The key stage is appointing a forensic examination of intellectual property objects. When rendering a decision, the judge relies on the conclusion of a certified expert, making proper formulation of questions critical.
When formulating questions, procedural opponents compete to define the knowledge level of the “person skilled in the art.” If it can be proven that at the priority date, any synthetic chemist possessing generally known manuals and publications could have achieved the claimed result via routine experimentation without creative effort, the inventive step is considered refuted. State-of-the-art materials may include journal articles, conference abstracts, patents from any country, dissertations, and public databases (e.g., PubMed or Chemical Abstracts).
Comprehensive Preventive Audit: Protecting the Commercial Release
The final stage of launching a medicinal product to market is integrating patent security with customs control and the protection of digital brand assets. Commercial success is shaped not only by ensuring the drug formula is free from competitors’ patent rights. It is equally critical to protect one’s own trademark, packaging design, and digital brand presence.
When a generic enters the market, it faces reverse threats: the appearance of gray parallel imports from lower-priced jurisdictions, counterfeits from unscrupulous pharma manufacturers, and domain hijacking by internet fraudsters.
- FTO Results Fixation: Obtaining a comprehensive Legal Opinion signed by a patent attorney and attorney with comparative formula tables.
- Registration Dossier Audit: Verifying the absence of indications or treatment methods covered by valid third-party secondary patents in the package leaflet.
- Registration of Own Trademarks: Obtaining certificates for the verbal product name and graphic packaging design in accordance with applicable trademark protection legislation.
- Entry into the Customs Register: Submitting applications and documents to customs authorities to automatically block the import of counterfeit and gray batches by competitors.
- Digital Compliance in State Services: Monitoring and updating statuses of title documents through intellectual property electronic portals.
- Reserving the Domain Landscape: Preemptively registering the medicine name in national domain zones, as well as monitoring international registries to prevent cybersquatting on platforms like EUIPO (European Union Intellectual Property Office) when expanding into EU markets.
Synchronizing these measures guarantees seamless distribution and robust protection of commercial investments in product launch.
Customs Register of Intellectual Property Objects: Risks
Registering a medicinal product trademark in the Customs Register of Intellectual Property Rights Objects is a mandatory step for national distributor protection. Once a trademark is entered into the register, customs inspectors at all checkpoints receive an algorithm for identifying unauthorized product batches.
If a third party attempts to import a generic analog or counterfeit under a similar name or with identical packaging design, customs clearance will be blocked automatically. Legal prevention in this case works doubly: the company secures an FTO immunity from others’ patents while simultaneously forming an unassailable customs border to protect its own brands from parasitic competition.
Synchronizing Patent Protection with Domain Infrastructure
Modern promotion of pharmaceutical products is impossible without creating promo websites, portals for doctors and patients, and educational platforms about specific diseases. However, companies frequently face cybersquatting: malicious actors track Ministry of Health registry publication orders and immediately register similar domain names for resale or to create fake online pharmacies.
Having a registered trademark allows obtaining access to premium national domains where registration is possible exclusively by the owner of the respective certificate. If cybersquatters capture the drug name in international zones (.COM, .ORG, .HEALTH), an effective instrument is resolving domain disputes under the UDRP procedure. Under the Uniform Domain-Name Dispute-Resolution Policy (UDRP) at the World Intellectual Property Organization (WIPO) Arbitration and Mediation Center, a domain name can be promptly retrieved and transferred to the legitimate drug manufacturer without lengthy national court proceedings.
Safe Product Market Launch: Final Recommendations
The patent freedom of a pharmaceutical product is not a one-time paper document, but a systematic business risk management strategy. A successful launch requires an integrated balance: deep technical FTO expertise, precise adherence to the procedural limits of the Bolar exception, a bold readiness to challenge competitors’ “evergreen” patents, and uncompromising protection of one’s own commercial designations and domain resources.
Given the duration of regulatory procedures in the pharmaceutical sector, initiating comprehensive patent and domain clearance is necessary at least 12–18 months prior to the planned product launch date. Proactive legal audits performed by specialists allow turning intellectual property from a source of potential million-dollar losses into the foundation of a stable and long-term commercial monopoly.
